ROR1 and B-cell chronic lymphocytic leukemia: Wnt5a could induce Rac1 activation to enhance proliferation and survival of ROR1-expressing CLL cells, even when treated with ibrutinib at concentrations that were effective in inhibiting BTK and B-cell-receptor (BCR) signaling [2].